{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:39:54Z","timestamp":1791430794582,"version":"4.3.3"},"reference-count":40,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP23K15773"],"award-info":[{"award-number":["JP23K15773"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Locally advanced or metastatic urothelial carcinoma is a genomically and molecularly heterogeneous disease associated with various clinical outcomes. We aimed to evaluate the association between the status of p53\/FGFR3 expression and the efficacy of enfortumab vedotin (EV) in metastatic urothelial carcinoma. We evaluated the association between p53 (abnormal vs. wild-type) or FGFR3 (high vs. low) expression determined by immunohistochemistry and response to EV in 28 patients with metastatic urothelial carcinoma. Overall, 60.7% showed abnormal p53, and 17.9% had high FGFR3 expression. The rates of objective response to EV were statistically higher in patients with abnormal p53 than in those with wild-type p53 (p = 0.038). Patients with pure urothelial carcinoma (n = 18) and low FGFR3 showed significantly better response to EV than those with high FGFR3. When the statuses of p53 and FGFR3 were combined, abnormal p53\/low FGFR3 (vs. wild-type p53\/high FGFR3) was strongly associated with favorable outcomes in both the entire cohort (p\u00a0= 0.002) and in cases of pure urothelial carcinoma only (p = 0.023). Immunohistochemically abnormal p53 tumors were found to respond well to EV, while high FGFR3 tumors had a poorer response. Thus, p53 and FGFR3 are potential biomarkers for predicting response to EV treatment in patients with urothelial carcinoma.<\/jats:p>","DOI":"10.3390\/ijms251910348","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:05:46Z","timestamp":1727323546000},"page":"10348","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma"],"prefix":"10.3390","volume":"25","author":[{"given":"Yujiro","family":"Nagata","sequence":"first","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Minato","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisami","family":"Aono","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Kimuro","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Higashijima","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikko","family":"Tomisaki","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-7769","authenticated-orcid":false,"given":"Hiroshi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Departments of Pathology & Laboratory Medicine and Urology, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"},{"name":"Department of Urology, Kurate Hospital, Kurate 807-1311, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"(2024, August 25). SEER Cancer Stat Facts: Bladder Cancer; National Cancer Institute: Bethesda, MD, USA, Available online: http:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/iju.15435","article-title":"Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan","volume":"31","author":"Hara","year":"2024","journal-title":"Int. J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.21873\/anticanres.16594","article-title":"Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World","volume":"43","author":"Minato","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kawahara, T., Hasizume, A., Uemura, K., Yamaguchi, K., Ito, H., Takeshima, T., Hasumi, H., Teranishi, J., Ousaka, K., and Makiyama, K. (2023). Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma. Cancers, 23.","DOI":"10.20944\/preprints202307.1978.v1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3390\/curroncol31020064","article-title":"Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study","volume":"31","author":"Minato","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/curroncol31020056","article-title":"Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions","volume":"31","author":"Endo","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Khoury, R., Saleh, K., Khalife, N., Saleh, M., Chahine, C., Ibrahim, R., and Lecesne, A. (2023). Mechanisms of Resistance to Antibody-Drug Conjugates. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119674"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315\u2013322.","DOI":"10.1038\/nature12965"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","article-title":"A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na\u00efve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.euo.2020.12.007","article-title":"Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy","volume":"4","author":"Sfakianos","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"153186","DOI":"10.1016\/j.prp.2020.153186","article-title":"Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations","volume":"216","author":"Hodgson","year":"2020","journal-title":"Pathol.-Res. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/his.13225","article-title":"p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant","volume":"71","author":"Hodgson","year":"2017","journal-title":"Histopathology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.drup.2006.03.001","article-title":"Restoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy","volume":"9","author":"Yu","year":"2006","journal-title":"Drug Resist. Updat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"a026070","DOI":"10.1101\/cshperspect.a026070","article-title":"p53 in the DNA-Damage-Repair Process","volume":"6","author":"Williams","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jindal, T., Zhu, X., Bose, R., Kumar, V., Maldonado, E., Deshmukh, P., Shipp, C., Feng, S., Johnson, M.S., and Angelidakis, A. (2023). Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1161089"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hoc.2014.11.003","article-title":"Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer","volume":"29","author":"McConkey","year":"2015","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_33","first-page":"8108","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder","volume":"63","author":"Bakkar","year":"2003","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lefort, F., Rhanine, Y., Larroquette, M., Domblides, C., Heraudet, L., Sionneau, B., Lambert, S., Lasserre, M., Robert, G., and Ravaud, A. (2023). Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice. Cancers, 15.","DOI":"10.3390\/cancers15235558"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline, version 1.1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.21873\/cgp.20375","article-title":"Receptor for Hyaluronic Acid-mediated Motility (RHAMM) Is Associated with Prostate Cancer Migration and Poor Prognosis","volume":"20","author":"Minato","year":"2023","journal-title":"Cancer Genom. Proteom."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","article-title":"Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: An immunohistochemical and nucleotide sequencing analysis","volume":"24","author":"Yemelyanova","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_38","first-page":"1389","article-title":"p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer","volume":"143","author":"Esrig","year":"1993","journal-title":"Am. J. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Satpayev","year":"2016","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10348\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:03:31Z","timestamp":1760112211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":40,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ijms251910348"],"URL":"https:\/\/doi.org\/10.3390\/ijms251910348","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}